Nova Pulse Ivf Clinic Profile
Key Indicators
- Authorised Capital ₹ 75.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 70.12 Cr
as on 15-11-2024
- Company Age 14 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 73.00 Cr
as on 15-11-2024
- Revenue 35.43%
(FY 2023)
- Profit 51.25%
(FY 2023)
- Ebitda 103.64%
(FY 2023)
- Net Worth -22.84%
(FY 2023)
- Total Assets 15.78%
(FY 2023)
About Nova Pulse Ivf Clinic
- CIN/LLPIN
U74900MH2010PTC375458
- Company No.
055474
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Oct 2010
- Date of AGM
29 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Nova Pulse Ivf Clinic?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shankar Kodukulla  | Company Secretary | Current | |
| Shobhit Agarwal | CEO | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vishal Bali | Nominee Director | 24-May-2019 | Current |
| Kumar Agarwal | Ceo and Director | 06-Aug-2019 | Current |
Ritesh Pandey  | Director | 30-Oct-2019 | Current |
Financial Performance of Nova Pulse Ivf Clinic.
Nova Pulse Ivf Clinic Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.43% increase. The company also saw a substantial improvement in profitability, with a 51.25% increase in profit. The company's net worth observed a substantial decline by a decrease of 22.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nova Pulse Ivf Clinic?
In 2022, Nova Pulse Ivf Clinic had a promoter holding of 97.11% and a public holding of 2.89%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rhea Healthcare Private LimitedActive 16 years 7 monthsVishal Bali and Ritesh Pandey are mutual person
Origin International Fertility Centre Private LimitedActive 17 years 6 monthsKumar Agarwal is a mutual person
Asian Institute Of Nephrology And Urology (Chennai) Private LimitedActive 7 years 3 monthsVishal Bali is a mutual person
- Asian Institute Of Nephrology And Urology Private LimitedActive 13 years 6 months
Vishal Bali is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 20 Aug 2020 | ₹73.00 Cr | Open |
How Many Employees Work at Nova Pulse Ivf Clinic?
Nova Pulse Ivf Clinic has a workforce of 1194 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nova Pulse Ivf Clinic, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nova Pulse Ivf Clinic's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
